JOSIE MONTEGAARD MSN, AGPCNP-BC
Prescription History 1871978502
Nurse Practitioner - Adult Health in Boston, MA

NPI Status: Active since July 23, 2015

Contact Information

450 BROOKLINE AVE
BOSTON, MA
ZIP 02215
Phone: (617) 582-7572

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOSIE MONTEGAARD MSN, AGPCNP-BC, an active Adult Health specialist practicing in Boston, MA. Our medical registry currently tracks 14 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 763 documented patient claims. Among these therapy options, the most frequently utilized medication is Imbruvica, which accounts for 173 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 162
30-Day Fills 347.2
Days Supply 10,390
MA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills43.9
Peer Average Days Supply1,226
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 548.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,629.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.75

State Avg Cost Per Claim

$26.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 49.0
Days Supply 1,470
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills105.3
Peer Average Days Supply3,110
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $275.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.47

State Avg Cost Per Claim

$16.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Atovaquone

Generic Formulation: AtovaquoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 40
30-Day Fills 54.2
Days Supply 1,581
MA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply789
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 53.8% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,968.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,124.21

State Avg Cost Per Claim

$865.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

Therapeutic Applications

Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 870
MA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills39.8
Peer Average Days Supply1,190
Conservative Utilization

This provider writes prescriptions for this formulation 25.6% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $405,820.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,993.80

State Avg Cost Per Claim

$13,620.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 24.0
Days Supply 720
MA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.3
Peer Average Days Supply430
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $285,180.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,962.77

State Avg Cost Per Claim

$14,357.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Eliquis

Generic Formulation: ApixabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 29.0
Days Supply 870
MA State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills123.2
Peer Average Days Supply3,403
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,783.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$699.33

State Avg Cost Per Claim

$792.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 173
30-Day Fills 173.0
Days Supply 4,894
MA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply884
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 476.7% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,546,341.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,718.74

State Avg Cost Per Claim

$14,871.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lorazepam

Generic Formulation: LorazepamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 214
MA State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills67.7
Peer Average Days Supply1,735
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $94.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.26

State Avg Cost Per Claim

$7.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 41.0
Days Supply 1,230
MA State Average Benchmarks
Peer Average Claims99.0
Peer Average 30-Day Fills219.7
Peer Average Days Supply6,505
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $356.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.75

State Avg Cost Per Claim

$16.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 100
MA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.6
Peer Average Days Supply119
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $212.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.63

State Avg Cost Per Claim

$10.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Prednisone

Generic Formulation: PrednisoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 31.0
Days Supply 762
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,107
Conservative Utilization

This provider writes prescriptions for this formulation 34.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $150.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.19

State Avg Cost Per Claim

$6.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 139
30-Day Fills 261.0
Days Supply 7,790
MA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply486
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 456.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,035.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.45

State Avg Cost Per Claim

$6.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 62.0
Days Supply 1,837
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply686
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,192.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$91.35

State Avg Cost Per Claim

$44.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 40
30-Day Fills 40.0
Days Supply 1,200
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply695
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 66.7% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $602,190.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,054.76

State Avg Cost Per Claim

$10,973.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOSIE MONTEGAARD MSN, AGPCNP-BC provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.